GLP-1-based therapy for obesity
US$ 24.40
retatrutide for obesity Weight loss with as compared to currently licenced Retatrutide Phase 3: 60% Achieved
Description
Current evidence suggests that most patients who tolerate treatment during the first year continue to do well later
Clinicians should also confirm medication access and insurance coverage before prescribing
doi: 10.1016/j.cmet.2019.01.017 323 TaylorAIIrwinNMcKillopAMPattersonSFlattPRGaultVA
Pleiotropic effects of GIP on islet function involve osteopontin
The emphasis moves from merely losing weight to living well in general
